The Next Test for Kite Pharma and Gilead: Anito-cel’s FDA Decision Looms
The spotlight is firmly on anito-cel, a novel CAR-T therapy for multiple myeloma co-developed by Gilead’s Kite Pharma and Arcellx, Inc. Gilead submitted a biologics License Submission (BLA) to the Food and Drug Administration (FDA) for anito-cel before the end of December, as revealed by Cindy Perettie, Executive Vice President of Kite Pharma [STAT+]. This submission marks a critical juncture for both companies, and for patients battling relapsed or refractory multiple myeloma.
understanding Anito-cel and its Innovative Approach
Anito-cel, also known as anitocabtagene autoleucel, represents a perhaps significant advancement in CAR-T therapy for multiple myeloma. Unlike traditional CAR-T approaches, anito-cel utilizes Arcellx’s innovative and compact D-Domain binder [[3]]. This unique design aims to enhance the therapy’s ability to target and eliminate myeloma cells while potentially reducing off-target effects.
CAR-T therapy,or Chimeric Antigen Receptor T-cell therapy,involves engineering a patient’s own immune cells (T cells) to recognize and attack cancer cells. In the case of multiple myeloma,CAR-T therapies are typically used when other treatments have failed,offering a potential lifeline for patients with limited options.
The Collaboration Between Kite Pharma and Arcellx
The growth of anito-cel is the result of a strategic global collaboration between Kite Pharma,a Gilead Company,and arcellx [[1]] and [[2]]. This partnership leverages Kite’s expertise in cell therapy manufacturing and commercialization with Arcellx’s innovative technology platform. The collaboration aims to accelerate the development and delivery of potentially transformative therapies to patients in need.
iMMagine-1 Trial: Pivotal Data and Future Prospects
The BLA submission is supported by data from the pivotal Phase 2 iMMagine-1 trial. New data from this study is expected to be presented at the American Society of Hematology (ASH) 2025 meeting [[2]], offering further insights into the efficacy and safety of anito-cel. The iMMagine-1 trial is evaluating anito-cel in patients with relapsed or refractory multiple myeloma (RRMM), a challenging-to-treat subset of the disease.
What’s Next? The FDA Review Process
With the BLA now in the hands of the FDA, the agency will begin a thorough review process. This typically involves evaluating the clinical trial data, manufacturing processes, and safety profile of the therapy. The FDA may convene an advisory committee to solicit expert opinions, and will likely request additional data from Gilead and Arcellx. The FDA is expected to make a decision in the coming months.
The potential approval of anito-cel would represent a significant step forward in the treatment of relapsed or refractory multiple myeloma, offering a new hope for patients who have fatigued other treatment options. The innovative D-Domain binder technology could potentially address some of the limitations of existing CAR-T therapies, leading to improved outcomes and a better quality of life for patients.
Published: 2026/01/17 18:28:14
